REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

21/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9202Xa&default-theme=true

RNS Number : 9202X  GSK PLC  20 February 2025

GSK plc (the 'Company')

 

Deferred Annual Bonus Plan Awards

On 17 February 2025, the Company granted awards to the Persons Discharging
Managerial Responsibilities ('PDMRs') listed below. The awards have been
granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred
Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.

Executive Directors and other members of the GSK Leadership Team are required
to defer part of any bonus earned into Ordinary Shares or American Depositary
Shares ('ADS') for three years. Under the terms of the Remuneration Policy
approved by shareholders in 2022, Executive Directors are required to defer
50% of bonus equivalent to the first 200% of salary into Ordinary Shares or
ADS with any portion in excess of 200% being deferred in full. Other members
of the GSK Leadership Team are required to defer 25% of bonus equivalent to
the first 170% of salary into Ordinary Shares or ADS with any portion in
excess of 170% being deferred in full.

The awards have been granted as restricted awards over ADS for US participants
and as nil-cost options over Ordinary Shares for all other participants.

The numbers of Ordinary Shares and ADS shown below are exclusive of dividend
reinvestment that will accrue during the deferral period.

 

Transaction notification

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Emma Walmsley
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              103,980

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Julie Brown
 b)  Position/status                          Chief Financial Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              68,129

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Diana Conrad
 b)  Position/status                          Chief People Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              15,257

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     James Ford
 b)  Position/status                          SVP and Group General Counsel, Legal and Compliance
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              23,784

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Sally Jackson
 b)  Position/status                          SVP, Global Communications and CEO Office
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              13,332

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Luke Miels
 b)  Position/status                          Chief Commercial Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              36,562

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Shobie Ramakrishnan
 b)  Position/status                          Chief Digital and Technology Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADS')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Deferred Bonus Award of ADS under the GlaxoSmithKline 2017 Deferred Annual
                                              Bonus Plan
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   $36.17               11,288

                                                                   .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     David Redfern
 b)  Position/status                          President, Corporate Development
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              21,151

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Regis Simard
 b)  Position/status                          President, Global Supply Chain
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              30,986

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Phil Thomson
 b)  Position/status                          President, Global Affairs
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              18,836

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Deborah Waterhouse
 b)  Position/status                          CEO, ViiV Healthcare and President, GSK Global Health
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              29,136

                                                                  .

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Tony Wood
 b)  Position/status                          Chief Scientific Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
                                              Deferred Annual Bonus Plan
 c)  Price(s) and volume(s)                                       Price(s)            Volume(s)
                                                                  £14.35              27,146

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-02-17
 f)  Place of the transaction                 N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEIFISEISELE